Fibro-inflammatory disease therapeutic - BLR Bio
Latest Information Update: 28 Jan 2026
At a glance
- Originator BLR Bio
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 05 Dec 2025 Preclinical trials in Inflammation in USA (unspecified route), prior to December 2025 (BLR Bio pipeline, December 2025)